Monkey CCL17/TARC ELISA Kit: Species-Specific Quantification for Th2 Inflammation Research

Why Species-Matched CCL17 Detection Matters

Th2 immune regulation, chemokine-driven cell migration, and allergic disease mechanisms form a busy intersection of immunology, dermatology, and respiratory research. CCL17, also called thymus and activation-regulated chemokine (TARC), sits precisely at that intersection. This CC chemokine is the high-affinity ligand of CCR4 and selectively recruits Th2 cells and regulatory T cells. It shapes atopic dermatitis, allergic asthma, and the remodeling of tumor immune microenvironments.

Quantifying CCL17 in non-human primate samples brings a particular technical difficulty. Rhesus and cynomolgus CCL17 share high sequence homology with the human protein, so cross-reactivity is a persistent risk. A human kit may still read monkey samples, but its specificity and calibration were never established for that matrix. Demand for assays validated on monkey serum, plasma, and cell culture supernatant keeps rising. That growth is driven by the widening use of macaque models in asthma, atopic dermatitis, and vaccine evaluation.

Core Design Logic: Species Matching and Dynamic Range Coverage

A dedicated monkey CCL17/TARC kit is built around two objectives. The capture and detection antibodies must recognize monkey CCL17 epitopes while minimizing binding to the human homolog. The working range must then span both the physiological baseline in monkey serum and the elevated concentrations recorded after disease induction.

Mainstream platforms use a sandwich format. A microplate is pre-coated with anti-monkey CCL17 capture antibody. CCL17 in the sample binds the solid-phase antibody, and an HRP-labeled detection antibody completes the sandwich complex. After TMB development, absorbance is read at 450 nm and is proportional to analyte concentration.

For a typical monkey CCL17/TARC kit, the detection range covers 15.63 pg/mL to 1000 pg/mL with a sensitivity of 4.431 pg/mL. Serum, plasma, cell culture supernatant, and tissue homogenate are all suitable sample types. Human kits often span only 7.8 to 500 pg/mL, so the monkey-specific format holds linearity at lower concentrations while still covering the pathological elevations seen in allergy models.

Conceptual diagram of elevated CCL17 levels in disease, divided into T-cell-associated pathology, non-T-cell-associated pathology, and diseases with unknown CCL17 function

CCL17 expression follows a distinctive pattern. In the thymus it is expressed constitutively and supports T cell migration after positive selection. In peripheral tissue it is produced mainly by dendritic cells, macrophages, endothelial cells, and keratinocytes. Allergen exposure or Th2 inflammatory signaling upregulates transcription and secretion, with cytokines such as IFN-gamma driving the response in keratinocytes and endothelium.

That pattern, constitutive in the thymus and inducible in the periphery, makes CCL17 a sensitive marker of Th2 inflammation, allergic disease activity, and tumor microenvironment remodeling. Sample collection protocol deserves attention because CCL17 concentrations differ between serum and EDTA plasma. Consistent handling is therefore essential for any longitudinal comparison. Many studies combine CCL17 with CCR4 expression, IgE, and eosinophil counts to profile Th2 response intensity.

Biological Functions of CCL17 in Th2 Immunity

Chemotaxis of Th2 Cells and Regulatory T Cells

The core function of CCL17 is CCR4-dependent chemotaxis. By engaging CCR4, it directs Th2-type CD4-positive T cells and FoxP3-positive regulatory T cells toward inflammatory sites. In allergic asthma, serum CCL17 is significantly higher than in healthy controls and correlates positively with total and free IgE. This relationship points to a central driving role in Th2 airway inflammation. Researchers can track CCL17 dynamics in monkey asthma models alongside CCR4-positive T cell infiltration to dissect the underlying molecular mechanism.

Local Inflammation and Tissue Remodeling in Allergic Disease

CCL17 is strongly overexpressed in atopic dermatitis lesions and in asthmatic airways. In atopic dermatitis, serum CCL17 correlates consistently with disease severity and reflects progression more reliably than IgE, LDH, or peripheral eosinophil counts. In allergic bronchopulmonary aspergillosis, CCL17 rises before clinical features appear and can be detected earlier than total IgE, which supports its potential as an early biomarker. Monkey models of allergic disease allow researchers to measure CCL17 across disease stages and link it to local inflammatory infiltration and tissue remodeling.

Tumor Immune Microenvironment and Treg Recruitment

Within tumors, CCL17 shows bidirectional regulation. In gastric cancer and MALT lymphoma, tumor-derived CCL17 recruits regulatory T cells through CCR4 and promotes immune suppression. Neutralizing the CCL17/CCR4 axis partially blocks Treg migration, whereas neutralizing CCL17 and CCL22 together abolishes Treg infiltration. In melanoma, however, elevated CCL17 tracks with better prognosis, so its function is tumor type dependent. Preclinical monkey samples combined with Treg density and immunotherapy response data can clarify that context dependence.

Research Applications in Non-Human Primate Models

Allergic Asthma and Th2 Airway Inflammation

Non-human primates offer unique value in asthma mechanism studies. The kit quantifies CCL17 in serum and bronchoalveolar lavage fluid to assess airway Th2 inflammation and intervention efficacy. Serum CCL17 correlates negatively with lung function measures such as FEV1%, which supports its use as a surrogate marker of airway inflammation.

Atopic Dermatitis and Skin Allergy Mechanisms

Monkey models reproduce the lesions and immune features of human atopic dermatitis. In lesional epidermis, keratinocytes produce CCL17 and drive the directed recruitment of Th2 cells into skin. Measuring CCL17 in serum and lesional tissue alongside severity scores and barrier function indicators helps evaluate anti-Th2 strategies.

Vaccine Immunogenicity and Th2 Bias Evaluation

Some adjuvants and antigen formulations can shift responses toward Th2 and raise allergy risk. Monitoring post-vaccination CCL17 helps assess the Th1/Th2 balance of vaccine-induced immunity. Rising CCL17 suggests Th2 bias and should be interpreted together with Th1 markers such as IFN-gamma.

Tumor Immunotherapy Response

CCL17-mediated Treg recruitment is one mechanism of tumor immune evasion. Measuring CCL17 in monkey tumor models, together with Treg infiltration density and checkpoint inhibitor response data, helps define the role of the CCL17/CCR4 axis in immunotherapy resistance.

Drug Intervention and Anti-Allergy Compounds

Anti-allergy drugs and natural active compounds can act by modulating CCL17 expression. Comparing CCL17 levels before and after intervention validates their effect on the Th2 chemotaxis pathway and provides an experimental basis for novel anti-allergy development.

Sample Handling and Assay Control

Data quality in monkey CCL17 ELISA depends on whether sample preparation and assay operation form a closed loop. Anticoagulant choice, centrifugation timing, and hemolysis control during collection determine CCL17 stability in the matrix. During detection, reagent pre-equilibration, pipetting precision, and consistent incubation conditions determine whether the antigen-antibody reaction runs to completion. A lapse at any step can be amplified in the final quantitative result, so the whole workflow belongs inside one quality control system.

Product Information

The Monkey CCL17/TARC OneStep ELISA Kit is optimized for rapid quantification of CCL17 in monkey serum, plasma, and cell culture supernatant. The full workflow completes within one hour, supporting allergic asthma model evaluation, atopic dermatitis mechanism studies, vaccine Th2 bias monitoring, and tumor immune microenvironment analysis.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.

Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.